Verspeeten Family Cancer Centre, Lawson Health Research Institute, London, ON N6A 5W9, Canada.
Verspeeten Family Cancer Centre, Lawson Health Research Institute, London, ON N6A 5W9, Canada; Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 3K7, Canada.
Cell Rep Med. 2024 Apr 16;5(4):101487. doi: 10.1016/j.xcrm.2024.101487. Epub 2024 Mar 27.
The gut microbiota influences anti-tumor immunity and can induce or inhibit response to immune checkpoint inhibitors (ICIs). Therefore, microbiome features are being studied as predictive/prognostic biomarkers of patient response to ICIs, and microbiome-based interventions are attractive adjuvant treatments in combination with ICIs. Specific gut-resident bacteria can influence the effectiveness of immunotherapy; however, the mechanism of action on how these bacteria affect anti-tumor immunity and response to ICIs is not fully understood. Nevertheless, early bacterial-based therapeutic strategies have demonstrated that targeting the gut microbiome through various methods can enhance the effectiveness of ICIs, resulting in improved clinical responses in patients with a diverse range of cancers. Therefore, understanding the microbiota-driven mechanisms of response to immunotherapy can augment the success of these interventions, particularly in patients with treatment-refractory cancers.
肠道微生物群会影响抗肿瘤免疫力，并能诱导或抑制对免疫检查点抑制剂（ICIs）的反应。因此，微生物群特征正被研究作为预测/预后生物标志物，以评估患者对 ICI 的反应，基于微生物组的干预措施作为与 ICI 联合应用的辅助治疗方法极具吸引力。特定的肠道常驻细菌会影响免疫疗法的有效性；然而，这些细菌如何影响抗肿瘤免疫力和对 ICI 的反应的作用机制尚不完全清楚。尽管如此，早期的基于细菌的治疗策略已经表明，通过多种方法靶向肠道微生物组可以增强 ICI 的有效性，从而改善各种癌症患者的临床反应。因此，了解免疫治疗反应的微生物群驱动机制可以提高这些干预措施的成功率，特别是在治疗抵抗性癌症患者中。
